Login
About Alexion
Our Leadership
Our Partnerships
Our Ethical Standards
Our History
Patient Focus
Advocacy
Patient Stories
Products
Soliris
®
PNH
aHUS
Strensiq
®
Kanuma
®
Research & Development
Our Pipeline
Development Programs
Investigator-Sponsored Research
Discovery Partnerships
Responsibility
Global Access to Medicines Policy
Main Menu
Careers
Job Opportunities
Why Choose Alexion
Culture
Compensation & Benefits
Work/Life Balance
Health & Wellness
Financial Security
Recognition & Rewards
Personal Growth & Development
Professional Development
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Select a Country
Investors
News
Contact
Search for:
North America
Canada
United States
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
United Kingdom
Asia Pacific
Australia
China
India
Japan
About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Home
»
Newsroom
»
Press Releases
Press Releases
Press Releases
Filter by Category
All Press Releases
Company Releases
Company Statements
Financial Releases
Product Releases
Sort by Year
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
Media
Inquiries
Media
Materials
Email
Alerts
All News Releases
Search:
New Research Presented at EHA Congress Shows That Soliris® Significantly Reduced Hemolysis in Never-Transfused Patients with PNH
June 7, 2009
HTML
PDF
New Study Results Verify That PNH Cells Are Found in Majority of Patients with Bone Marrow Failure Syndromes
May 29, 2009
HTML
PDF
Researchers to Report on the Investigational Use of Alexion's Soliris® (Eculizumab) to Prevent Antibody-Mediated Rejection in High-Risk Kidney Transplant Patients
May 28, 2009
HTML
PDF
Alexion Submits NDA in Japan for Soliris® (eculizumab) as a Treatment for Patients with PNH
April 1, 2009
HTML
PDF
Alexion Joins NORD and EURORDIS in Supporting the Goals of Rare Disease Day
February 27, 2009
HTML
PDF
Alexion's Soliris® (eculizumab) Receives Marketing Approval in Australia for All Patients with PNH
February 25, 2009
HTML
PDF
Alexion's Soliris® (eculizumab) Receives Marketing Approval in Canada for All Patients with PNH
January 29, 2009
HTML
PDF
New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris® (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
January 29, 2009
HTML
PDF
Soliris® Receives Orphan Drug Designation in Japan
January 12, 2009
HTML
PDF
Alexion Pharmaceuticals To Report Fourth Quarter and Full Year 2008 Results on February 12, 2009
January 12, 2009
HTML
PDF
« first
‹ previous
…
38
39
40
41
42
43
44
45
46
…
next ›
last »
